Provided by Tiger Fintech (Singapore) Pte. Ltd.

Repligen

150.62
+8.185.74%
Post-market: 149.97-0.6160-0.41%17:18 EDT
Volume:498.44K
Turnover:74.44M
Market Cap:8.44B
PE:-327.44
High:150.87
Open:143.92
Low:142.79
Close:142.44
Loading ...

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

StockStory
·
11 Mar

TD Cowen Keeps Their Buy Rating on Repligen (RGEN)

TIPRANKS
·
05 Mar

Q4 2024 908 Devices Inc. Earnings Call

Thomson Reuters StreetEvents
·
05 Mar

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

Benzinga
·
05 Mar

Repligen deal can expand bioprocessing opportunities, says RBC Capital

TIPRANKS
·
05 Mar

Repligen’s Strategic Acquisition of 908 Devices’ Bioprocessing Assets Boosts Buy Rating

TIPRANKS
·
04 Mar

Repligen Buys 908 Devices' Desktop Portfolio for $70 Million

MT Newswires Live
·
04 Mar

Repligen Buys 908 Devices Bioprocessing Analytics Portfolio for $70 Million

Dow Jones
·
04 Mar

Repligen Purchases Bioprocessing Analytics Portfolio From 908 Devices

THOMSON REUTERS
·
04 Mar

Repligen Corp: Purchase Consideration Is a Payment of $70 Mln in Cash

THOMSON REUTERS
·
04 Mar

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

GlobeNewswire
·
04 Mar

Repligen Delays 2024 Yearly Report Filing

TIPRANKS
·
04 Mar

Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB) and Repligen (RGEN)

TIPRANKS
·
03 Mar

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Telix Pharmaceuticals Ltd. (OtherTLPPF), Repligen (RGEN) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
24 Feb

Buy Recommendation for Repligen Driven by Strong Performance and Positive Growth Outlook

TIPRANKS
·
23 Feb

Repligen’s Earnings Call: Growth Amid Challenges

TIPRANKS
·
22 Feb